Einat Brill Almon, VP, Product Development at Protalix BioTherapeutics, Inc. (PLX), sold 93,954 shares at $9.39 ($884K) on 2009-10-16, disclosed to the SEC on 2009-10-19.
Scheduled sale ($884k) by VP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.39 | 28,000 | $263K | 29.7% |
| 2 | $9.39 | 23,680 | $222K | 25.1% |
| 3 | $9.43 | 38,320 | $361K | 40.9% |
| 4 | $9.48 | 3,954 | $37K | 4.2% |
| Total | $9.41 avg | 93,954 | $884K | 100% |
| Filing → |
| PLX | SELL | 2010-09-08 | $404K | — | Filing → |
| PLX | SELL | 2009-07-08 | $280K | — | Filing → |
| PLX | SELL | 2009-05-19 | $160K | — | Filing → |